TY - JOUR T1 - Association between antiphospholipid antibody type and level and pulmonary manifestations in APS JF - European Respiratory Journal JO - Eur Respir J VL - 44 IS - Suppl 58 SP - P2346 AU - Milica Kontic AU - Ljudmila Stojanovic AU - Aleksandra Djokic AU - Nenad Ilijevski Y1 - 2014/09/01 UR - http://erj.ersjournals.com/content/44/Suppl_58/P2346.abstract N2 - Introduction:Antiphospholipid syndrome (APS) may manifest itself as a primary or secondary disease, most commonly in the context of Systemic Lupus Erythemathosus (SLE) with various pulmonary manifestations in its occurrence. Aim of this study was to observe and investigate association between antiphospholipid antibodies type and level and pulmonary manifestations in APS.Methods:This paper reports the first results from the Serbian National APS registry, which started in 2006.Our study comprises of 329 patients:214 patients with primary APS and 115 patients with secondary APS. Antiphospholipid antibody (aPL) analysis included detection of aCL (IgG/IgM), beta2GPI (IgG/IgM), and LA and serves to evaluate correlations with distinct pulmonary manifestations.Results:In the SAPS group major pulmonary arterial thrombosis are more prone to high aCL IgG levels (above100PLU/ml), p=0.006; ARDS were correlated with medium aCL IgG levels (41-99PLU/ml),p=0.047 and fibrosis alveolitis with medium aCL IgG levels (41-99PLU/ml),p=0.002. In the PAPS group, fibrosis alveolitis was correlated with medium beta2GPI IgM levels (p=0.0001).Presence of aCL IgG antibodies were more common in patients with SAPS (p=0,037). We revealed statistical significance considering the presence of LA and pulmonary embolism and infarction (p=0,03) and pulmonary microthrombosis (p=0,03) in SAPS, and between presence of LA with pulmonary microthrombosis(p=0,03) in PAPS group. Conclusion:Our study showed that certain aPL antibody type and levels correlated with distinct pulmonary manifestation, suggesting their predictive or protective role. ER -